Related Experiment Video
Updated: Jun 8, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Increased mortality among persons infected with hepatitis C virus
Lars Haukali Omland1, Peter Jepsen, Henrik Krarup
1Department of Infectious Diseases, Rigshospitalet, Copenhagen, Denmark. omland@dadlnet.dk
Hepatitis C virus (HCV) infection increases long-term mortality risk, especially for younger individuals who face a higher chance of unnatural death. This study quanties risks and causes of death in HCV patients.
Area of Science:
- Hepatology
- Public Health
- Epidemiology
Background:
- Long-term mortality in hepatitis C virus (HCV) patients remains poorly understood.
- Few studies have adequately controlled for confounders or analyzed age-specific mortality risks.
- Absolute risk estimates and specific causes of death in HCV cohorts are lacking.
Purpose of the Study:
- To determine the long-term mortality associated with HCV infection.
- To investigate how mortality risk varies with age at diagnosis and follow-up duration.
- To identify specific causes of death in HCV-infected individuals.
Main Methods:
- A cohort of 10,991 HCV patients was compared to an age- and sex-matched general population cohort in Denmark.
- Regression analysis adjusted for socioeconomic factors, psychiatric illness, comorbidities, and substance abuse.
- Causes of death and the impact of HCV on mortality were analyzed concerning age and follow-up length.
Main Results:
- HCV patients exhibited lower income, more comorbidities, psychiatric issues, and substance abuse.
- Ten-year survival rates significantly decreased with age, from 84.1% (20-29 years) to 21.1% (70+ years).
- The adjusted 18.2-fold increased mortality risk for younger HCV patients (20-29 years) was primarily due to unnatural causes, while older patients (70+ years) faced a 1.6-fold increased risk from non-liver natural causes.
Conclusions:
- Hepatitis C virus infection is linked to significantly increased long-term mortality.
- Younger HCV patients (20-29 years) are at a substantially elevated risk of death from unnatural causes.
- Mortality risk and causes of death in HCV patients are influenced by age and follow-up duration.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cytomegalovirus Disease